Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ ) 0.4244 -0.0034 (-0.79%) Streaming Delayed Price Updated: 3:59 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Mainz Biomed N.V. - Ordinary Shares < Previous 1 2 3 4 5 6 Next > Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good July 10, 2024 This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday July 09, 2024 It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning! Via InvestorPlace Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket July 09, 2024 Via Benzinga Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session July 08, 2024 Via Benzinga mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment July 02, 2024 The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens... Via Benzinga Exposures COVID-19 Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight June 26, 2024 On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt,... Via Benzinga Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks June 21, 2024 Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks Via News Direct Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate June 05, 2024 Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate Via News Direct Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon June 04, 2024 On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co... Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session June 04, 2024 Via Benzinga Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket May 29, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday May 29, 2024 It's time to start the day with a breakdown of the biggest pre-market stock movers traders are going to want to watch on Wednesday morning! Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 17, 2024 The final day of trading this week is here and we have the biggest pre-market stock movers worth watching on Friday morning! Via InvestorPlace Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game May 16, 2024 On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... Via Benzinga mRNA Is Promising A Breakthrough In Fighting Cancer April 29, 2024 When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it... Via Benzinga Exposures COVID-19 The Pharmaceutical Industry Finds Itself At A Historical Crossroads April 10, 2024 Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: Via Benzinga MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023 April 09, 2024 MYNZ stock results show that Mainz Biomed beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. Via InvestorPlace Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era April 02, 2024 Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. Via Benzinga Exposures COVID-19 Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening February 28, 2024 When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track... Via Benzinga Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment February 22, 2024 Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several... Via Benzinga Topics Intellectual Property Exposures COVID-19 Intellectual Property 2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front February 07, 2024 On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine... Via Benzinga 2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge February 02, 2024 --News Direct-- Via News Direct Topics Death Exposures Death Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle February 01, 2024 On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a... Via Benzinga Exposures COVID-19 2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge February 01, 2024 The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the... Via Benzinga Topics Death Exposures Death 2024 Marks a New Era Of Pharmaceutical Innovation January 09, 2024 With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned... Via Benzinga Exposures COVID-19 2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer December 29, 2023 During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. Via Benzinga Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study December 19, 2023 Via Benzinga Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session December 05, 2023 Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session December 05, 2023 Via Benzinga While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer December 05, 2023 Obesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in... Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.